AB1564 would let a specific type of California cannabis licensee — a licensed microbusiness holding an M‑license with outdoor cultivation — ship medicinal cannabis directly to medicinal patients in state. The bill ties that authorization to a dense set of product, sourcing, carrier, labeling and recordkeeping constraints rather than opening broad home delivery.
Why it matters: the measure creates a narrow channel for small vertically integrated outdoor operators to reach patients without a storefront, while excluding many common product types (vapes, infused edibles, indoor flower) and imposing provenance verification and retention duties that shift compliance work onto microbusinesses and their carriers.
At a Glance
What It Does
Authorizes an eligible licensed microbusiness (retail + manufacturing + distribution + outdoor cultivation) to ship medicinal cannabis to in‑state medicinal patients, provided shipments follow enumerated product exclusions, testing, and provenance rules, are pre‑paid, and are delivered only by common carriers that use their own employees.
Who It Affects
Eligible microbusinesses with an M‑license and outdoor cultivation activity; medicinal cannabis patients with valid physician recommendations or ID cards; common carriers that handle these shipments; regulators and track‑and‑trace administrators; testing laboratories that must certify shipped product.
Why It Matters
The bill creates a regulated retail‑to‑patient shipping pathway limited to outdoor‑sourced ingredients and low‑risk extraction methods, privileging certain cultivation and manufacturing practices and imposing new proof‑of‑source and recordkeeping burdens that change compliance priorities for small operators.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill authorizes direct shipments only from a licensed microbusiness that holds an M‑license and whose licensed activities include retail sale, manufacturing, distribution and outdoor cultivation. Shipments must go by a common carrier that uses only its own employees (no subcontracted or gig drivers) and may not exceed the possession limits already in state law for a single day.
Not all products can be shipped. AB1564 disallows inhalable and battery‑powered devices, vape oil/cartridges, inhalable concentrates, infused flower and prerolls, infused beverages, synthetic or chemically converted cannabinoids or terpenes, products made with volatile solvent extractions, and any cannabis ingredient not sourced in line with the bill’s outdoor‑sourcing rule.
It does allow a short list of items — tinctures, topicals, suppositories, full‑spectrum oils (e.g., FECO/RSO), outdoor‑grown flower (not infused), and outdoor‑sourced seeds — but only when those manufactured items are produced at the microbusiness using nonvolatile, mechanical, or infusion extraction techniques and when all ingredients meet the sourcing limits in the track‑and‑trace requirement.Operationally the bill puts a number of concrete duties on the microbusiness. Payment must be collected prior to shipment, and the retail sale is deemed to occur where and when payment is received; title transfers to the patient when the shipment is handed over to the carrier.
The carrier must obtain the signature of an individual at least 21 years old at delivery, and packages must be labeled to that effect. Every shipment must be entered into inventory records and the statewide track‑and‑trace system showing that shipped cannabis was sourced entirely from the microbusiness’s own licensed premises or from up to five licensed outdoor cultivation premises.
The retailer must retain patient identification and physician recommendation records (and, for qualified patients whose physician was verified, a written certification) for multi‑year retention periods. The bill also requires existing laboratory testing and track‑and‑trace compliance for shipped products and assigns retailer tax responsibility to the microbusiness.Finally, the bill clarifies that a common carrier that conveys medicinal cannabis under these rules is not, solely for that conveyance, in violation of state or local law and that such transportation does not count as delivery or transportation under the division.
The measure defines key terms (including volatile/nonvolatile solvents, tinctures, topicals, concentrates and prerolls) and contains an express sunset date of January 1, 2030.
The Five Things You Need to Know
The carrier may not subcontract delivery: shipments must be handled only by the common carrier’s own employees.
Shipments are limited by California Health & Safety Code Section 11362.77 possession limits for a single day.
A microbusiness must prove all shipped cannabis is sourced from its own licensed premises or from no more than five outdoor licensed cultivation sites, and record that provenance in the track‑and‑trace system.
Retail sale is treated as occurring when payment is received (title transfers when the product is handed to the carrier), and the microbusiness is responsible for any retailer taxes.
The authorization is temporary: the section automatically sunsets and is repealed on January 1, 2030.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Who may ship and the carrier requirement
This subsection establishes eligibility: only a licensed microbusiness with an M‑license that includes retail, manufacturing, distribution and outdoor cultivation may ship medicinal cannabis. It requires shipments be carried by a common carrier that uses only its own employees, which effectively prohibits subcontracting or third‑party gig drivers for these deliveries. Practically, that narrows the set of carriers that can participate and creates an operational compliance threshold for microbusinesses arranging logistics.
Possession limits and a narrow banned/allowed product list
The bill caps daily shipment quantities to existing state possession limits (H&S §11362.77). It then draws a detailed line between products that cannot be shipped (vapes, batteries, inhalable concentrates, infused products, volatile‑extraction products, synthetic cannabinoids, and indoor‑grown flower) and a specific set that can be shipped (certain tinctures, topicals, suppositories, full‑spectrum oils, and outdoor flower/seeds). Those allowed products are conditioned on manufacturing methods and ingredient sourcing, so simply labeling something as a tincture or topical is not enough — the extraction technique and ingredient provenance must meet the statute’s standards.
Payment, title transfer, age verification, labeling, testing and retention
The microbusiness must collect payment prior to shipment; the retail transaction occurs where and when payment is received, while legal title passes to the patient once the shipment is handed to the carrier. The carrier must obtain an adult (21+) signature at delivery and packages must state that requirement conspicuously. The retailer must enter shipments into its inventory and the statewide track‑and‑trace system, perform required laboratory testing on shipped products, and retain patient ID and physician recommendation records for multi‑year periods (with longer retention required where the business verifies a physician recommendation). These duties create layered compliance — sales, logistics, age‑verification and long‑term records all intersect.
Provenance requirement: own premises or up to five outdoor sites
All shipped cannabis must be sourced entirely from the microbusiness’s own licensed premises or from up to five outdoor cultivation premises holding specific outdoor license types (small, medium, specialty, specialty cottage). The bill forces microbusinesses to maintain end‑to‑end traceability in the mandated track‑and‑trace system that links each shipped product back to those source sites. That creates both an enforcement lever for regulators and a supply constraint for sellers who cannot augment outdoor‑sourced ingredients with indoor or volatile‑extracted inputs.
Physician checks for qualified patients and retailer tax duties
When serving a qualified patient with a physician’s recommendation, the microbusiness must verify the physician’s licensure status with relevant California medical boards and keep a copy of patient or caregiver government ID. The microbusiness acts as the retailer for shipped products and bears applicable retailer taxes. Together these provisions fold medical‑patient validation into seller due diligence and make the shipper fully responsible for retail tax compliance.
Legal clarifications, key definitions, and expiration
The bill states that a common carrier conveying medicinal cannabis under its rules is not in violation of state law or local ordinance solely for that conveyance and that the transport does not count as delivery/transport under the division — an immunity designed to encourage carrier participation. It includes granular statutory definitions (volatile/nonvolatile solvents, tinctures, concentrates, tablets, etc.) to reduce ambiguity about permitted extraction methods. The section is explicitly time‑limited, repealing itself on January 1, 2030.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicinal cannabis patients with mobility or access barriers — they gain a regulated route to receive certain outdoor‑sourced, lab‑tested medical products without visiting a dispensary.
- Licensed outdoor microbusinesses that hold M‑licenses — they receive a new retail channel to sell directly to patients beyond physical storefronts, potentially expanding market reach for vertically integrated operators.
- Small outdoor cultivators (outdoor small/medium/specialty/specialty cottage) — inclusion as acceptable ingredient sources creates potential new demand for outdoor‑grown flower and seeds.
- Track‑and‑trace and compliance vendors — the intensified provenance and long‑term retention requirements will increase demand for systems that can document sourcing, billing, and medical verification.
- Common carriers willing to use their own employees — the bill clarifies they will not be deemed to violate state or local laws solely for conveying these shipments, reducing legal uncertainty for eligible carriers.
Who Bears the Cost
- Licensed microbusinesses — they absorb additional manufacturing constraints (nonvolatile extraction only for allowed products), provenance obligations, multi‑year record retention, testing and taxation responsibilities, all of which raise compliance costs and operational complexity.
- Indoor cultivators and manufacturers relying on volatile extractions — the measure excludes indoor‑grown flower and volatile‑extracted products from this shipping pathway, restricting market access for those producers.
- Common carriers that want to participate but normally subcontract — firms that rely on subcontracting or gig networks must restructure operations or decline participation because the bill bars subcontracted delivery for these shipments.
- State regulators and local enforcement bodies — they face new workload to audit track‑and‑trace provenance claims, verify physician licensure checks, and enforce product‑type restrictions across many small operators.
- Patients seeking certain product formats (vapes, infused edibles, inhalable concentrates) — their options are reduced under this shipping channel because those product types are excluded even if available in retail stores.
Key Issues
The Core Tension
The bill balances two legitimate aims — increasing patient access to medical cannabis from small, vertically integrated outdoor operators and protecting public health by limiting shipped products to lower‑risk, traceable formats — but in doing so it tightens supply and raises compliance costs. The central dilemma is whether narrower, safer product rules and strict provenance standards justify reduced product choice and higher operational burdens that may limit the number of providers willing or able to participate.
The bill resolves one problem — creating a narrow, regulated direct‑to‑patient channel for small outdoor microbusinesses — by shifting several hard choices into implementation. First, provenance enforcement is only as strong as track‑and‑trace fidelity and audit capacity.
Requiring shipments be sourced from the microbusiness’s premises or up to five outdoor sites tightens supply chains but will be difficult to police if operators reuse inputs, commingle batches, or if the track‑and‑trace system lacks item‑level granularity. That raises both regulatory burden and the risk of noncompliant products slipping through if audits are underfunded.
Second, the extraction and product restrictions (nonvolatile/mechanical/infusion only for allowed manufactured items, blanket bans on vapes and volatile extracts) prioritize lower‑risk formats but also exclude many commonly used medical delivery forms. Patients and clinicians who prefer dosing precision or inhalation routes will find fewer options, potentially pushing some users to the unregulated market.
Additionally, the carrier restriction against subcontracting will exclude many modern logistics providers that rely on third‑party networks, narrowing participation to carriers with captive workforces or integrated last‑mile operations. Finally, the long retention periods for medical and verification records create privacy and storage considerations for microbusinesses and increase their compliance exposure if records are mishandled.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.